JNJ · News · 20260916N

Oncology Pipeline Progress

JOHNSON & JOHNSON · 2026-09-16 · Importance 23 · Surprise 24

Johnson & Johnson reported positive clinical-trial results for RYBREVANT-based regimens in EGFR-mutated non-small cell lung cancer. The Phase 2b COPERNICUS study showed improved tolerability, while the Phase 3 PAPILLON trial reported the longest median overall survival cited for EGFR exon 20 insertion NSCLC. The findings strengthen J&J’s oncology portfolio and support efforts to offset future patent losses and legal challenges with newer medicines.

Key facts

• Johnson & Johnson announced positive new clinical trial results for its RYBREVANT-based regimens in EGFR-mutated non-small cell lung cancer (NSCLC). source
• The Phase 2b COPERNICUS study showed improved tolerability for Johnson & Johnson's RYBREVANT-based regimens. source
• The Phase 3 PAPILLON trial demonstrated the longest reported median overall survival in EGFR exon 20 insertion non-small cell lung cancer for Johnson & Johnson's regimen. source
• Johnson & Johnson said these clinical findings strengthen its oncology portfolio and support its strategy to offset patent losses and legal challenges with new innovative medicines. source